The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ:SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those ...
Controversial Securities and Exchange Commission accounting guidance known as SAB 121 has been rescinded. SAB 121 has been viewed as a significant obstacle preventing banks from providing custody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback